





Biobanking: how it works and why it is important?

Michael D. Jenkinson

Clinical Senior Lecturer and Honorary Consultant Neurosurgeon University of Liverpool & The Walton Centre, Liverpool, UK

michael.jenkinson@liv.ac.uk

TBTC Nurse & AHP Study Day, Birmingham 19th May 2017

Running order

Why biobank?

Biobanking models?

Requirements for a biobank

How we do it in Liverpool

Future of biobanking in the UK


1. Why biobank?

Patient's perspective


- Most prevalent solid tumour in children
- Commonest cause of cancer death in children
- 1/3 cancer patients develop brain mets

- 3rd leading cause of cancer-related death among men between 15 – 54 years
- 4th leading cause of cancer-related death among women between 15 – 34 years





5 year survival



Patient experience of biobanking and the value of research

- My personal experience was brilliant, but I had no prior knowledge
- We're none of us as smart as all of us
- Important to understand and respect everyone's areas of expertise
- Patients want to be involved but it needs to be managed
- Raising awareness is important



"Tissue is the issue" Human samples in research

- Patients know their samples are important but don't have enough information
- They understand the need to link symptoms to the disease process
- They understand the need to be able to predict the effects of new treatments
- Patients can be a big driver in ensuring their tissue is collected

Search

Home About Cancer Genomics

Cancers Selected for Study

Research Highlights

Publications

Home > Cancers Selected for Study > Glioblastoma Multiforme

Glioblastoma Multiforme 🔝

Last Updated: January 03, 2014

What is glioblastoma multiforme?

Glioblastoma Multiforme (GBM) is a fast-growing type of malignant brain tumor that is the most common brain tumor in adults. In 2010, more than 22,000 Americans were estimated to have been diagnosed and 13,140 were estimated to have died from brain and other nervous system cancers. GBM accounts for about 15 percent of all brain tumors and occurs in adults between the ages of 45 to 70 years. Patients with GBM have a poor prognosis and usually survive less than 15 months following diagnosis. Currently there are no effective long-term treatments for this disease. View additional information on brain tumors.

What have The Cancer Genome Atlas (TCGA) researchers learned about GBM?

Over the course of six years of study and two journal publications, TCGA researchers have:

 Established a new subtype of GBM that affects younger adults and has an increased survival rate. A subset of GBM tumors had specific chemical changes called methylation of a large

Sample Collection Complete	Data Publicly Available
✓.	✓
Multimedia	
+ SIma MRI	ge: Glioblastoma -
+ Ima	age: Glioblastoma
M.D., M	eo: Neil Hayes, .P.H., Explains indings on

But limited clinical annotation How relevant are the results to routine clinical practice?

each patient to the most effective therapies. See more information about TCGA brain tumor subtype studies.

Glioblastoma (2:51)

Podoset: Spanish

Beyond genomic - the other 'omics'





Proteomics



Metabolomics



All depend on high quality annotated human biospecimens

Validation Translation (independent data set) Patient/Clinic **Discovery**

Biobank

2. Biobanking models

Single national biobank

-versus-

Network of biobanks

The CCLG Tissue Bank is the UK's largest unique collection of tumour, DNA and other tissue samples from childhood cancer patients.

CCLG Tissue Bank





The CCLG Tissue Bank is the UK's largest unique collection of tumour, DNA and other tissue samples from childhood cancer patients.

Paeds brain tumours: 400 new cases / year Full clinical annotation and samples <100% complete

Royal Hospital for Sick Children



Southampton General Hospital

EDINBURGH Royal Hospital for Sick Children

CCLG Tissue Bank



BRAIN UK

World's first national virtual brain bank











BRAIN UK is a collaboration between 26 NHS

Neuropathology Centres across the UK, giving effective coverage of 90% of UK population. The British

Neuropathological Society, British Neuro-oncology Society,

Brain Tumour Network, Medical Research Council and

National Cancer Research Institute Brain Tumour Clinical

Studies Group have provided input into and support for the project.



Adult primary brain tumours: ~10,500 new cases / year

Adult metastases: ~27,000 new cases / year


No / basic clinical annotation!

3. Resources for biobanking


Patient



Surgeon



Neuropathologist




Laboratory staff




Hardware & consumables

(from routine NHS resources!)



Top tumour nurses!



The essential paperwork

NHS

National Institute for Health Research

Clinical Research Network

Certificate of Completion Michael Jenkinson

has completed

Introduction to Good Clinical Practice (GCP)
e-learning course

- Ethics approval / Informed consent
- Anonymised data
- Disclose that discovery may have commercial value
- Disclose academic and commercial partners
- Governance structure / oversight
- Tissue quality assurance

	UN TUMOUR ORTH WEST	The Walton Centre 166 Foundation Trust Tel (Walton): 0151 529 5675 e-mail: Andrew Brode-lin@thewaltoncer Michael_enkinso@thewaltoncer Please stick patient hospi	Tel (CCC): tre.nhs.uk e-mail: Bri entre.nhs.uk Dav	ge Cancer Centre Nº6 Foundation Trust 0151 482 7851 an.I.Haylock@clatterbridgecc.nhs d.Husband@clatterbridgecc.nhs tya.Shenoy@clatterbridgecc.nhs	uk s.uk	
CONS	SENT FORM			WRTB no:		
Title o	of Project:					
	Nervous Sys	stem Tissue and/or Blo				
	(Tı	umour and non-tumour		on)		
		Walton Research hers: Mr A Brodbelt, Mr M Je rgeons, Dr D Crooks, Dr B Haylock	nkinson, Ms C Gilke		Plea Init box	
1.	and I understan	have read and understand the in d that my participation is volunta ny reason, w ithout my medical car	ry and that I am free	to withdraw at any time		
2.	I understand that sections of any of my medical records from The Walton Centre, Clatterbridge Cancer Centre or elsewhere may be looked at and information taken from them to be analysed in strict confidence by responsible individuals from the research team or from regulatory authorities where it is relevant to my taking part in research. I give permission for these individuals to have access to my records.					
3.	3. Consent for storage and use in current and future research projects: I agree that the samples I have given and the information gathered about me can be stored by the Tissue Bank, Neuropathology unit at The Walton Centre for current and future projects, subject to additional project specific ethical approval.					
4.	Walton Centre I	hat some of these projects may l NHS, including researchers workin mercial companies.				
5.	I agree to give samples/data taken, as a gift, for research as detailed in the patient information sheet and I am aware that I am not entitled to any financial gain.					
	understanding to unlikely to have	rch: I understand that my sample he genetic influences on tumours, any implications for me personally	but that the results of	these investigations are		
	Name, Date and	1 Sign	D-t-	Classitus		
Name	of Patient:		Date:	Signature:		
	n taking consent erent from resea		Date:	Signature:		
Name	of Researcher:		Date:	Signature:		
White	copy for Tumour E	eing to participate in this resea	ital notes & Pink copy f	or consultee/patient		
		ne Walton Centre or Clatterbridge Cand valtoncentre.nhs.uk/ www.clatte		ww htnw.org.uk/		
Wales F		REC No 15/WA/0385	Version 5	01/10/2015		

4. Biobanking in Liverpool

- 1995 2010:
 - Project specific ethical approval
 - New ethics for every new project
 - Time consuming
 - Could only target eligible patients for collection
 - Missed opportunity to collect samples from
 - rare brain tumours e.g. pineal
 - AND common tumours e.g. meningioma!

Established 2011 – Dr Carol Walker









NHS Foundation Trust

Tel (Walton): 0151 529 5675

e-mail: Andrew.Brodbelt@thewaltoncentre.nhs.uk Michael.Jenkinson@thewaltoncentre.nhs.uk Tel (CCC): 0151 482 7851

e-mail: Brian.Haylock@clatterbridgecc.nhs.uk David.Husband@clatterbridgecc.nhs.uk Aditya.Shenoy@clatterbridgecc.nhs.uk


Websites: www.thewaltoncentre.nhs.uk/ www.clatterbridgecc.nhs.uk/ www.btnw.org.uk/

Patient Information Sheet for tumour and non-tumour sample donation

Nervous System Tissue and/or Blood Collections for Research Walton Research Tissue Bank

Name of Researchers: Mr A Brodbelt, Mr M Jenkinson, Ms C Gilkes, other Walton Centre Consultant Neurosurgeons, Dr D Crooks, Dr B Haylock, Dr D Husband, Dr A Shenoy

We would like to invite you to take part in our research study. Before you decide we would like you to understand why the research is being done and what it would involve for you. One of our team will go through the information sheet with you and answer any questions you have. We'd suggest this should take about 30 minutes. Talk to others about the study if you wish. Ask us if there is anything that is not clear.



Embed biobanking within the clinical service

WRTB Recruitment (Jan-Dec 2016)

Tumour type	Not clear	GD I	GD II	GD III	GD IV	Total
Astrocytoma	_	2	15	8	_	25
Oligoastrocytoma	_	_	3	1	_	4
Oligodendroglioma	_	_	9	3	_	12
Ependymoma	_	1	1	2	_	4
Gliomas (infiltrating)		_	2	2	_	4
Glioblastoma (GBM)	_	_	_	_	90	90
Gliosarcoma	_	_	_	_	1	1
Total Gliomas		•	•	•	•	140
Meningiomas	1	38	23	0	_	62
Pitutary Adenoma						30
Metastases						48
Schwannoma	_	21	_	_	_	21
Haemangioblastoma	_	4	_	_	_	4
Lymphoma						2
Others						36
Grand total						343

WRTB Recruitment (Jan-Dec 2016)

No	t clear GD I	GD II	GD III	GD IV	Total
VRTB				2016	5
otal Patients				343	
otal Frozen tissu	es			220	2
otal Blood samp				305	
enerated)
erum samples				610	
lasma samples				610	10
ell fraction samp	oles			305	2
DTA blood samp	les			0	3
					L
amples released	1				
issue samples re	leased			131	
lood samples rel	leased			6	5
· · · · · · · · · · · · · · · · · · ·					

WRTB projects supported

WRTB Established	2011
Total Projects (2011-2016)	31
Total Ongoing/Active Projects	18
Type of Project (tumour based)	Number
High Grade Gliomas	8
Low Grade Gliomas	9
Metastases	5
Meningiomas	4
Others	5
Total	31
BRAIN UK Projects	3

Brain metastases











Meningioma



Glioma





5. Future of UK biobanking (Swiss versus Greek bank)

 Patients feel biobanks have a duty to make sure the tissue they donate is used for research






Linking to existing data sets

- Biobanks are resource intensive
- Can we link tissue to existing data sets?
 - E.g. National Cancer Registry
- Can patients contribute to their own data sets?
 - E.g. online repositories
- Can AHPs promote biobanking / contribute to data collection?

Advanced biobanking initiatives

- Multiples samples for intratumoural heterogeneity
- Longitudinal samples for evolutionary biology
 - primary and recurrent glioma
 - low to high grade transformation
- Paired samples from metastases for clonal evolution

Prospective study of leading edge



The Walton Centre

NHS Foundation Trust

Scientific meritocracy

- Fully annotated samples are a valuable resource
- Access to high quantity of brain tumour tissue is competitive
- Samples should go to the best research project

Improved networking

- Existing prospective biobanks
- Standardise SOPs
- Set targets for tumour types and samples
- Align collection to scientific questions

6. Conclusions

Patients value the opportunity to contribute

Collaborative working (clinic + science=translational)

Tumour biology / Identifying new targets for therapy

Future patient benefit

7. Acknowledgements / Collaborations

Tumour CNS

Jan Holding

Toni Thorpe

Helen Moore

Alison Rodway

Anna Crofton

Consultants

Andrew Brodbelt

David Lawson

E Chavredakis

Paul Eldridge

Jibril Farah

Katie Gilkes

Anna Visca

Trainees

Rasheed Zakaria

David GIraldi

Neuropathology lab

Khaja Syed (WRTB)

Nitika Rathi

Neil Moxham

Carrie Chadwick

Wallis Simpson-Hayes

Amanda Davies

Neuroradiology

Kumar Das

Maneesh Bhojak

Samantha Mills





















